BICO (STO: BICO) introduced its second divestiture since Maria Forss took over as President and CEO in November 2023. Following the sale of Ginolis final yr, BICO has now entered an settlement to promote its Nanoscribe model to LAB14 for €26 million. The transaction is predicted to shut within the fourth quarter of 2024, aligning with BICO’s up to date BICO 2.0 technique.
In keeping with Forss, the offloading is a part of BICO’s ongoing give attention to the life sciences sector: “The divestment of Nanoscribe is a significant step in delivering on our up to date technique, which was launched throughout our Capital Markets Day in September. Nanoscribe is a worthwhile and secure enterprise; nonetheless, it has its largest potential and buyer base outdoors life science and is due to this fact concluded as non-core for BICO going ahead.”
As of November 21, 2024, BICO’s inventory closed at SEK 34.62 ($3.12). Over the previous 12 months, the inventory has declined by roughly 27%, reflecting the corporate’s restructuring efforts and market reactions to its strategic realignment.
BICO CEO Maria Forss. Picture courtesy of BICO.
Nanoscribe’s Profile and Market Influence
In Could 2021, beneath the management of then-CEO Erik Gatenholm, BICO (previously Cellink) acquired Nanoscribe to enhance BICO’s present product portfolio, together with boosting the model’s bioprinting capabilities. By combining Nanoscribe’s microstructural bioprinting know-how with BICO’s macrostructural bioprinting experience, the corporate aimed to create extra reasonable tissue architectures, together with vascularization and cell assist buildings.
Nanoscribe’s know-how was anticipated to facilitate the event of consumables similar to implants, microneedles, microporous membranes, and instruments for omics functions, producing extra recurring income. The acquisition aligned with BICO’s broader bioconvergence technique. By incorporating Nanoscribe’s two-photon polymerization (2PP) know-how, BICO sought to remain aggressive within the miniaturization of gadgets throughout a variety of functions, notably in life sciences.
Recognized for its groundbreaking 2PP know-how, Nanoscribe has been a frontrunner in high-resolution 3D printing functions. Its latest innovation, the Quantum X align, received the 2024 European Convention on Optical Communication (ECOC) Business Award within the “Chip-Scale Packaging/Optical Sub-Meeting” class.
This recognition highlights the model’s pioneering position in photonic integration, with improvements similar to Aligned 2-Photon Lithography (A2PL), a method for immediately 3D printing exactly aligned optical elements, and Two-Photon Grayscale Lithography (2GL), a proprietary know-how that makes use of dynamic voxel tuning to create detailed 3D microstructures with unprecedented velocity and accuracy.
In the meantime, the Quantum X align is significant for industries requiring exact and dependable optical connections. With lateral alignment accuracy right down to 100 nanometers and compatibility with supplies like silicon, indium phosphide, and glass, it’s used to 3D print elements similar to optical couplers and freeform micro-optics. It interconnects for photonic chips and optical fibers. These functions make it extremely valued in photonics manufacturing. Regardless of its success, the corporate’s main market lies outdoors life sciences—a key consider BICO’s choice to promote the model.
Quantum X align. Picture courtesy of Nanoscribe.
The transaction is predicted to convey a revenue of about 10% in comparison with the worth recorded in BICO’s books on the finish of the third quarter of 2024. The precise quantity may change relying on change charges and when the deal is finalized. What’s extra, the cash from the sale might be used to repay a part of BICO’s long-term debt, which, as of the most recent obtainable information, stands at roughly SEK1.4 billion ($126 million), together with loans and bonds owed to a number of collectors.
In keeping with BICO, Nanoscribe might be handled as a discontinued operation in BICO’s monetary stories from This fall 2024, with the ultimate monetary affect to be disclosed within the upcoming year-end report 2024, which might be reported on February 19, 2025.
BU Researcher Mustafa Çağatay Karakan makes use of Nanoscribe’s 3D printer to make scaffolds important for rising coronary heart tissues on the White Lab. Picture courtesy of 3DPrint.com.
Taking on the Nanoscribe reins might be LAB14, a German firm specializing in superior manufacturing options like nano- and microfabrication applied sciences. LAB14’s portfolio consists of firms centered on semiconductor manufacturing, microelectronics, and supplies science, suggesting that Nanoscribe will discover a extra aligned dwelling beneath its new possession. Nanoscribe might be becoming a member of eight sister firms, together with Heidelberg Devices, which makes direct-write lithography programs; Osiris Worldwide, for gear utilized in semiconductor and microsystems know-how; and Nanosurf, which makes atomic power microscopes, amongst others.
Nanoscribe’s management, together with co-founders Martin Hermatschweiler (CEO) and Michael Thiel (CSO), is predicted to proceed driving the corporate’s revolutionary efforts, making certain a easy transition and sustained development beneath LAB14.
Nanoscribe founders Michael Thiel (left) and Martin Hermatschweiler (proper), with CFO Lars Tritschler (center). Picture courtesy of Nanoscribe
BICO’s Strategic Path
The sale of Nanoscribe follows the November 2023 divestiture of Finnish firm Ginolis, which was offered by means of a administration buyout for a symbolic €1. Ginolis had additionally been deemed a non-core asset because of its post-pandemic market challenges. Each strikes present that BICO is dedicated to its new BICO 2.0 technique, concentrating assets on life sciences.
The corporate’s up to date technique emphasizes profitability and scalability within the life sciences sector. Through the second quarter of 2024, BICO reported secure gross sales and optimistic EBITDA throughout all enterprise areas regardless of a unstable market atmosphere. The proceeds from divestitures, coupled with operational changes, strengthen the corporate’s place in its core markets.
Cell culturing with Nanoscribe’s Quantum X bio. Picture courtesy of Nanoscribe.
Below the brand new technique, BICO now has eight subsidiaries, specializing in core areas inside life sciences. Nonetheless, this leaves room to marvel which firm is likely to be subsequent in its quest to streamline operations. Whereas lots of its subsidiaries, similar to Cellink, Visikol, and MatTek, have clear and direct connections to life sciences, others could have a broader focus or serve industries outdoors BICO’s sharpened life sciences technique. This might affect the chief’s choices to refine its portfolio additional.
Trying Forward, the upcoming Q3 report, set for launch on November 26, 2024, will present extra perception into the corporate’s monetary efficiency and roadmap beneath Forss’s management. Within the meantime, for Nanoscribe, the transition to LAB14 may mark a possibility to increase its affect in markets outdoors life sciences, from photonics to optical communication.
Subscribe to Our E mail Publication
Keep up-to-date on all the most recent information from the 3D printing business and obtain info and gives from third occasion distributors.
